Literature DB >> 21383064

Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia.

Nicholas C Wolff1, Silvia Vega-Rubin-de-Celis, Xian-Jin Xie, Diego H Castrillon, Wareef Kabbani, James Brugarolas.   

Abstract

mTORC1 is a critical regulator of cell growth that integrates multiple signals and is deregulated in cancer. We previously reported that mTORC1 regulation by hypoxia involves Redd1 and the Tsc1/Tsc2 complex. Here we show that Redd1 induction by hypoxia is tissue dependent and that hypoxia signals are relayed to mTORC1 through different pathways in a tissue-specific manner. In the liver, Redd1 induction is restricted to the centrilobular area, and in primary hepatocytes, mTORC1 inhibition by hypoxia is independent of Redd1. Furthermore, Tsc1/Tsc2 and Arnt (Hif-1β) are similarly dispensable. Hypoxia signaling in hepatocytes involves Lkb1, AMP-activated protein kinase (AMPK), and raptor. Differences in signal relay extend beyond hypoxia and involve AMPK signaling. AMPK activation (using 5-aminoimidazole-4-carboxamide riboside [AICAR]) induces raptor phosphorylation and inhibits mTORC1 in both mouse embryo fibroblasts (MEFs) and hepatocytes, but whereas mTORC1 inhibition is Tsc1/Tsc2 dependent in MEFs, it is independent in hepatocytes. In liver cells, raptor phosphorylation is essential for both AMPK and hypoxia signaling. Thus, context-specific signals are required for raptor phosphorylation-induced mTORC1 inhibition. Our data illustrate a heretofore unappreciated topological complexity in mTORC1 regulation. Interestingly, topological differences in mTORC1 regulation by the tumor suppressor proteins Lkb1 and Tsc1/Tsc2 may underlie their tissue specificity of tumor suppressor action.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383064      PMCID: PMC3133225          DOI: 10.1128/MCB.01393-10

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  64 in total

Review 1.  The tuberous sclerosis complex.

Authors:  Peter B Crino; Katherine L Nathanson; Elizabeth Petri Henske
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

2.  DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Authors:  Timothy R Peterson; Mathieu Laplante; Carson C Thoreen; Yasemin Sancak; Seong A Kang; W Michael Kuehl; Nathanael S Gray; David M Sabatini
Journal:  Cell       Date:  2009-05-14       Impact factor: 41.582

3.  RTP801 is a novel retinoic acid-responsive gene associated with myeloid differentiation.

Authors:  Sigal Gery; Dorothy J Park; Peter T Vuong; Renu K Virk; Claudia I Muller; Wolf-K Hofmann; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2007-04       Impact factor: 3.084

4.  PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase.

Authors:  Yasemin Sancak; Carson C Thoreen; Timothy R Peterson; Robert A Lindquist; Seong A Kang; Eric Spooner; Steven A Carr; David M Sabatini
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

5.  Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway.

Authors:  Hyeon-Ok Jin; Sungkwan An; Hyung-Chahn Lee; Sang-Hyeok Woo; Sung-Keum Seo; Tae-Boo Choe; Doo-Hyun Yoo; Seung-Bum Lee; Hong-Duck Um; Su-Jae Lee; Myung-Jin Park; Jong-Il Kim; Seok-Il Hong; Chang-Hun Rhee; In-Chul Park
Journal:  Cell Signal       Date:  2007-01-20       Impact factor: 4.315

Review 6.  AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy.

Authors:  D Grahame Hardie
Journal:  Nat Rev Mol Cell Biol       Date:  2007-10       Impact factor: 94.444

7.  PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.

Authors:  Lifu Wang; Thurl E Harris; Richard A Roth; John C Lawrence
Journal:  J Biol Chem       Date:  2007-05-17       Impact factor: 5.157

8.  The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.

Authors:  Noriko Oshiro; Rinako Takahashi; Ken-ichi Yoshino; Keiko Tanimura; Akio Nakashima; Satoshi Eguchi; Takafumi Miyamoto; Kenta Hara; Kenji Takehana; Joseph Avruch; Ushio Kikkawa; Kazuyoshi Yonezawa
Journal:  J Biol Chem       Date:  2007-05-21       Impact factor: 5.157

9.  PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex.

Authors:  Bruno D Fonseca; Ewan M Smith; Vivian H-Y Lee; Carol MacKintosh; Christopher G Proud
Journal:  J Biol Chem       Date:  2007-06-29       Impact factor: 5.157

10.  PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis.

Authors:  Kathrin Thedieck; Pazit Polak; Man Lyang Kim; Klaus D Molle; Adiel Cohen; Paul Jenö; Cécile Arrieumerlou; Michael N Hall
Journal:  PLoS One       Date:  2007-11-21       Impact factor: 3.240

View more
  32 in total

Review 1.  Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer.

Authors:  Biplab Dasgupta; Rishi Raj Chhipa
Journal:  Trends Pharmacol Sci       Date:  2015-12-20       Impact factor: 14.819

Review 2.  The role of mammalian target of rapamycin (mTOR) in the regulation of pancreatic β-cell mass: implications in the development of type-2 diabetes.

Authors:  Jianling Xie; Terence P Herbert
Journal:  Cell Mol Life Sci       Date:  2011-11-09       Impact factor: 9.261

Review 3.  Regulation of mTORC1 by PI3K signaling.

Authors:  Christian C Dibble; Lewis C Cantley
Journal:  Trends Cell Biol       Date:  2015-07-06       Impact factor: 20.808

4.  Hantavirus interferon regulation and virulence determinants.

Authors:  Erich R Mackow; Nadine A Dalrymple; Velasco Cimica; Valery Matthys; Elena Gorbunova; Irina Gavrilovskaya
Journal:  Virus Res       Date:  2014-01-08       Impact factor: 3.303

5.  REDD1/DDIT4-independent mTORC1 inhibition and apoptosis by glucocorticoids in thymocytes.

Authors:  Nicholas C Wolff; Renée M McKay; James Brugarolas
Journal:  Mol Cancer Res       Date:  2014-03-10       Impact factor: 5.852

Review 6.  Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift.

Authors:  Doug Medvetz; Carmen Priolo; Elizabeth P Henske
Journal:  Mol Cancer Res       Date:  2014-10-08       Impact factor: 5.852

7.  Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

Authors:  Blanka Kucejova; Samuel Peña-Llopis; Toshinari Yamasaki; Sharanya Sivanand; Tram Anh T Tran; Shane Alexander; Nicholas C Wolff; Yair Lotan; Xian-Jin Xie; Wareef Kabbani; Payal Kapur; James Brugarolas
Journal:  Mol Cancer Res       Date:  2011-07-28       Impact factor: 5.852

8.  Hypoxia suppresses conversion from proliferative arrest to cellular senescence.

Authors:  Olga V Leontieva; Venkatesh Natarajan; Zoya N Demidenko; Lyudmila G Burdelya; Andrei V Gudkov; Mikhail V Blagosklonny
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-30       Impact factor: 11.205

9.  Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1.

Authors:  Tram Anh Tran; Lisa Kinch; Samuel Peña-Llopis; Lutz Kockel; Nick Grishin; Huaqi Jiang; James Brugarolas
Journal:  Mol Cell Biol       Date:  2013-07-22       Impact factor: 4.272

10.  Hypoxia and gerosuppression: the mTOR saga continues.

Authors:  Olga V Leontieva; Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2012-09-17       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.